Search

US-12616782-B2 - Use of mitochondria to treat and/or prevent tendon injury or its related disease

US12616782B2US 12616782 B2US12616782 B2US 12616782B2US-12616782-B2

Abstract

The present invention provides a second use of mitochondria, which can cure a tendon injury-related disease and prevent a disease caused by a tendon injury. Specifically, the mitochondria disclosed in the present invention have the effect of repairing injured tendon cells and accelerating the healing of the tendon cells. Therefore, by administering a predetermined amount of mitochondria or a composition containing a predetermined amount of mitochondria to a part with a tendon injury, wound healing of the part with the tendon injury can be promoted, thus achieving the effect of repairing the injured tendon and further preventing a joint disease caused by the tendon injury or inflammation.

Inventors

  • Han-Chung CHENG
  • Chih-Kai Hsu
  • Hui-Ching TSENG
  • An-Ling CHENG

Assignees

  • TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD.

Dates

Publication Date
20260505
Application Date
20210319

Claims (12)

  1. 1 . A method for treating and/or preventing a tendon injury-related disease, comprising administering to a subject an effective amount of a composition, wherein the composition includes mitochondria and platelet-rich plasma (PRP); the dose of the mitochondria in the composition is at least 15 μg; and the concentration of the platelet-rich plasma is 5% (v/v) and more.
  2. 2 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the tendon injury-related disease is tendonitis.
  3. 3 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the tendon injury-related disease comprises a symptom of tendon inflammation or swelling.
  4. 4 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the tendon injury-related disease is a tendon lesion.
  5. 5 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the dose of the mitochondria in the composition ranges from 15 μg to 80 μg.
  6. 6 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the content of the growth factor in the platelet-rich plasma is 522.54 ng/ml and more.
  7. 7 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the platelet-rich plasma includes at least 1,000,000 platelets/μl.
  8. 8 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the platelet-rich plasma includes 155.2±57.67 ng/ml of PDGF-BB, 236.07±222.1 ng/ml of IGF-1, 488.76±240.77 ng/ml of TGF-β1, 242.29±97.64 ng/ml of VEGF and 82.24±64.51 ng/ml of bFGF.
  9. 9 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the mitochondria have an intact structure and are obtained by the following steps: (a) collecting cells comprising mitochondria; (b) subjecting the cells to homogenization and centrifugation, and collecting the resulting precipitate, wherein the precipitate is the mitochondria.
  10. 10 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the tendon injury-related disease is a joint disease or a ligament injury-related disease, which is caused by a tendon injury or tendon inflammation.
  11. 11 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the composition further includes a blood product, which includes at least one of the following growth factors: PDGF-BB, IGF-1, TGF-β1, VEGF, and bFGF.
  12. 12 . The method for treating and/or preventing a tendon injury-related disease of claim 1 , wherein the dose of the mitochondria in the composition ranges from 30 μg/ml to 160 μg/ml.

Description

TECHNICAL FIELD The present invention relates to a second use of mitochondria, and in particular to a use of mitochondria to treat and/or prevent a tendon injury or its related disease. BACKGROUND Tendons are dense connective tissues that link bones and muscles together, which can transfer muscle power to bones and enable joint movement. Therefore, the place where the muscle connects to the tendon or the place where the tendon connects to the bone may bear a relatively great mechanical load, such that the above areas are prone to injury, thus affecting the function of the tendon. Tendon injuries usually occur in people who overuse their tendons, repeat similar movements over a long period of time, and repeatedly and excessively press or pull their tendons, leading to tendon tear. If the injury fails to heal, the tendon will become less flexible and is unable to withstand tension. In this case, a tendon lesion is likely to occur and the patient cannot exert force or feels a pain in the part where the lesion occurs, such as biceps tendonitis, rotator shoulder tendonitis, knee patellar tendonitis, Achilles tendonitis, calcific tendonitis, lateral epicondylitis, internal humeral epicondylitis, a ligament injury, ligament inflammation, or the like. The repair and slow alleviation of the tendon injury often requires long-term treatment or rehabilitation. In order to improve the treatment efficiency, regenerative therapy, such as the platelet-rich plasma (PRP) proliferative therapy, is currently used clinically for the repair of the tendon, ligament, and muscle injuries. That is, by administering PRP to apart with a tendon injury, the injured part of the tendon can be healed efficiently. However, the PRP proliferative therapy is not effective in all patients with the tendon injury. That is, when the patient has the poor coagulation function or the tendon is too severely injured, the PRP treatment has a limited effect. Because tendon and ligament injuries are common health problems today, it is in urgent need to provide an effective method or composition that can improve the treatment efficiency. SUMMARY The main objective of the present invention is to provide a second use of mitochondria. Because a certain amount of mitochondria can repair injured tendon cells, alleviate or inhibit the inflammatory response of the tendon cells, and improve the healing rate of the tendon cells, when a person has a tendon injury-related disease or symptom, the tendon injury-related disease can be treated and/or a joint disease caused by the tendon injury can be prevented by administering a certain amount of mitochondria or a composition containing the mitochondria. Another objective of the present invention is to provide a composition that contains mitochondria and other substances containing a growth factor, which can greatly improve the efficiency of repairing the tendon cells or alleviating inflammation of the tendon cells, so as to reduce the chance of complications related to a tendon injury or inflammation. In order to achieve the foregoing objectives, an example of the present invention discloses a composition that contains mitochondria and a blood product, where the blood product contains at least one growth factor. The blood product is platelet-rich plasma (hereinafter PRP), and the PRP contains a variety of growth factors, such as PDGF-BB, IGF-1, TGF-β1, VEGF, bFGF, etc. For example, the composition disclosed in the present invention contains mitochondria and PRP, where the dose of the mitochondria ranges from 5 μg to 80 μg and preferably from 15 μg to 40 μg; and the concentration of PRP is preferably 5 v/v % (vol %) or more. Another example of the present invention discloses a use of mitochondria to prepare a composition for treating a tendon injury-related disease or preventing a joint disease. Therefore, by administering a certain amount of mitochondria to a part with a tendon injury, the repair of the tendon injury can be accelerated and tendon inflammation can be alleviated, thus achieving the effect of treating the tendon injury-related disease or preventing the joint disease. The dose of the mitochondria in the composition is 40 μg or more. In order to improve the efficiency of treating the tendon injury-related disease or preventing the joint disease or a ligament injury-related disease, in an example of the present invention, the composition further contains PRP, where the concentration of the PRP is 5% or more, and the composition is preferably composed of PRP with the concentration of 5% or more and mitochondria with the dose of 40 μg or more. In an example of the present invention, the joint disease or ligament injury-related disease is caused by a tendon injury or tendon inflammation, such as arthritis, joint inflammation, ligament inflammation, a ligament injury, etc. In an example of the present invention, the tendon injury-related disease is a tendon lesion, tendonitis, or any disease having a symptom of t